Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI-H)” will be presented by Dr Dung Le, MD, The John Hopkins University, a Senior Investigator of the trial, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-14, 2021). Dr. Michael J. Overman, MD, Anderson Cancer Center, Principal Investigator of the trial provided the narration (e-poster presentation).

Poster presentation details:

• Poster number: 410
• Date: November 13, 2021
• Time: 12:30-14:00 and 19:00-20:30 EST
• Location: Poster Hall, Walter E. Washington Convention Center, Washington, D.C.

For more information: https://www.sitcancer.org/home